摘要
目的探讨哮喘-慢性阻塞性肺疾病重叠综合征噻托溴铵联合布地奈德福莫特罗对患者气道重塑及免疫炎症反应的影响。方法回顾性选取2018年1月至2020年1月本院哮喘-慢阻肺重叠综合征患者100例,依据治疗方法分为噻托溴铵联合布地奈德福莫特罗治疗组(联合治疗组,n=50)、单独布地奈德福莫特罗治疗组(单独治疗组,n=50)两组,统计分析两组患者的症状评分、肺功能、气道重塑指标、免疫、炎症反应、临床疗效、不良反应发生情况。结果联合治疗组患者治疗后较治疗前的ACT评分升高幅度,CAT评分、mMRC评分降低幅度,RV/VTC降低幅度,IC/TLC、FEV_(1)升高幅度,WT、TDR、WA降低幅度,Th1、Th2、Th1/Th2升高幅度,血清hs-CRP、EOS水平降低幅度均显著高于单独治疗组,差异有统计学意义(P<0.05)。联合治疗组治疗的总有效率显著高于单独治疗组,差异有统计学意义(P<0.05)。联合治疗组不良反应发生率显著低于单独治疗组,差异有统计学意义(P<0.05)。结论哮喘-慢阻肺重叠综合征噻托溴铵联合布地奈德福莫特罗治疗较单独布地奈德福莫特罗治疗更能有效减轻患者气道重塑及免疫炎症反应。
Objective To investigate the effects of tiotropium bromide combined with budesonide and formoterol fumarate on airway remodeling and immune inflammatory response in patients with asthma-chronic obstructive pulmonary disease(COPD)overlap syndrome(ACOS).Methods A total of 100 patients with ACOS admitted to our hospital from January 2018 to January 2020 were retrospectively selected and divided into two groups based on the treatment method.They were the treatment group of tiotropium bromide combined with budesonide and formoterol fumarate(the combined treatment group,n=50)and the treatment group of budesonide and formoterol fumarate individually(the individual treatment group,n=50).The symptom scores,lung function,airway remodeling index,immunity,inflammatory response,clinical efficacy,and occurrence of adverse reactions(ARs)in the two groups were statistically analyzed.Results The increase in the score of Activated Clotting Time of whole blood(ACT),decrease in the score of COPD Assessment Test(CAT)and the score of Modified Medical Research Council Dyspnea Scale(mMRC),decrease in residual volume(RV)/VTC,increase in inspiratory capacity(IC)/Total Lung Capacity(TLC)and forced expiratory volume in one second(FEV_(1)),decrease in WT,TDR and WA,increase in Th1,Th2 and Th1/Th2,decrease in the levels of serum hypersensitive C-reactive protein(hs-CRP)and eosinophil count(EOS)in the combined treatment group were significantly higher than those in the individual treatment group,the difference was statistically significant(P<0.05).The total effective rate of the combined treatment group was significantly higher than that in the individual treatment group,the difference was statistically significant(P<0.05).The incidence of ARs in the combined treatment group was significantly lower than that in the individual treatment group,the difference was statistically significant(P<0.05).Conclusion In the treatment of ACOS,tiotropium bromide combined with budesonide and formoterol fumarate is more effective than budesonide and formoterol
作者
王琴
朱齐琦
黄小红
WANG Qin;ZHU Qiqi;HUANG Xiaohong(Department of Geriatrics,Jiujiang No.1 People′s Hospital in Jiangxi Province,Jiujiang 332000,China;Department of Respiration,Jiujiang No.1 People′s Hospital in Jiangxi Province,Jiujiang 332000,China)
出处
《中国现代医生》
2021年第29期68-71,76,共5页
China Modern Doctor
基金
江西省卫生健康委科技计划项目(202120057)。
关键词
哮喘-慢性阻塞性肺疾病重叠综合征
噻托溴铵
布地奈德福莫特罗
气道重塑
免疫
炎症反应
Asthma-chronic obstructive pulmonary disease overlap syndrome
Tiotropium bromide
Budesonide and formoterol fumarate
Airway remodeling
Immunity
Inflammatory response
